Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

MT Newswires Live12-09

Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.1%.

Arcellx (ACLX) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.

Agios Pharmaceuticals (AGIO) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.

Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490202207?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 22:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490202207","market":"sg","top_or_hot":-1,"title":"Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday","media":"MT Newswires Live","content":"<html><body><p> Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the <a href=\"https://laohu8.com/S/EEMA\">iShares</a> Biotechnology ETF (IBB) up 0.1%.</p><p>Arcellx (ACLX) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.</p><p>Agios Pharmaceuticals (AGIO) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.</p><p>Beam <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSector Update: Health Care Stocks Edge Higher Pre-Bell Monday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 22:04 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.1%.Arcellx (ACLX) shares were up 8.6% pre-bell ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4581","symbol_name":"高盛持仓","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490202207","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490202207","pubTimestamp":1733753090,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund  and the iShares Biotechnology ETF  up 0.1%.Arcellx  shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Agios Pharmaceuticals  shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.Beam Therapeutics  said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4581":"高盛持仓","BK4588":"碎股","XLV":"健康照护类股ETF-SPDR","AGIO":"Agios Pharmaceuticals, Inc.","IBB":"生物科技指数ETF-iShares Nasdaq","BK4139":"生物科技","BK4535":"淡马锡持仓","BK4556":"基因编辑","BK4505":"高瓴资本持仓","ACLX":"ARCELLX, INC.","BK4585":"ETF&股票定投概念","BEAM":"Beam Therapeutics, Inc."},"translate_title":"行业更新：医疗保健股周一盘前小幅走高","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACLX":0.9,"AGIO":0.9,"BEAM":0.9,"IBB":0.9,"XLV":0.9},"content_text":"Health care stocks were edging higher premarket Monday, with The Health Care Select Sector SPDR Fund (XLV) and the iShares Biotechnology ETF (IBB) up 0.1%.Arcellx (ACLX) shares were up 8.6% pre-bell Monday after the company said preliminary data from a phase 2 trial of anitocabtagene autoleucel in patients with relapsed or refractory multiple myeloma demonstrated a 97% overall response rate.Agios Pharmaceuticals (AGIO) shares were down 7.5% even after the company said Sunday the phase 3 study of its experimental drug mitapivat to treat adults with transfusion-dependent alpha- or beta-thalassemia, a rare blood disease, met primary and secondary goals.Beam Therapeutics (BEAM) said Sunday new data for its engineered stem cell antibody evasion conditioning platform showed that conditioning and in vivo selection with an anti-CD117 antibody allowed engraftment of base-edited hematopoietic stem cells in a non-human primate model. Beam shares were up 6.6% pre-bell Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490202207"}